CNBX Pharmaceuticals (OTCQB: CNBX) has acquired a controlling interest in TaGeza Biopharmaceuticals Ltd., enhancing its position in the cancer immunotherapy market. The acquisition will see TaGeza's co-founder, Prof. Benjamin Dekel, continue as Chief Scientist, while CNBX Chairman Gabriel Yariv steps in as CEO of TaGeza. TaGeza specializes in developing next-generation immunotherapies targeting cancer stem cells and tumor-initiating cells. This strategic move positions CNBX to leverage established antibody drug conjugate (ADC) therapies, projected to exceed $16 billion in annual sales by 2026.
CNBX Pharmaceuticals Inc. (OTCQB: CNBX) has filed a new patent application under the PCT titled "COMPOSITIONS COMPRISING CANNABINOIDS AND METHODS OF USE THEREOF IN THE TREATMENT OF CANCER." This application focuses on drug candidates for treating Colorectal Cancer, Breast Cancer, and Melanoma, specifically as Neoadjuvant Cancer Therapy. The company is enhancing its pipeline with specialized medical doctors and has an IP portfolio of 8 patent families, including 7 granted patents. CNBX is also advancing its drug candidate CNBX RCC-33, preparing for a pre-IND meeting with the FDA.
CNBX Pharmaceuticals has announced the filing of a patent application entitled "COMPOSITION AND METHOD FOR TREATING CANCER WITH CANNABINOIDS" with the US Patent and Trademark Office and the Israel Patent Office on October 12, 2022. This application is related to drug candidates in its pipeline, including CNBX RCC-33, targeting colorectal cancer. The company has an extensive IP portfolio of 8 patent families, with 7 granted patents and 18 pending, focusing on innovative cancer treatments.
CNBX Pharmaceuticals (OTCQB: CNBX) announced the peer-reviewed publication of its preclinical study titled "The Effect of Isolated Cannabinoid Extracts on Polypoid Colorectal Tissue" in the International Journal of Molecular Sciences. The study indicates a "possible future therapeutic value" for PLP-33, a proprietary drug candidate for colonic polyps. Conducted with 22 patients, the study observed a synergistic interaction of cannabinoid compounds against colonic polyps, alongside a differential toxic effect on polypoid versus healthy tissues.
CNBX Pharmaceuticals Inc. (OTCQB: CNBX) has announced the receipt of a patent grant from IP Australia for its innovation titled System and Method for High Throughput Screening of Cancer Cells, effective from May 2016 until May 2036. This patent bolsters CNBX's intellectual property portfolio, now comprising 8 families with 7 granted and 18 pending patents, all focused on cannabinoid-based cancer treatments. This strategic advancement supports the company's ongoing research and development efforts in the cancer treatment sector.
CNBX Pharmaceuticals Inc. (OTCQB: CNBX) announced on May 5, 2022, that it received a Grant of Patent from the Hong Kong Patent Registry for its patent titled System and Method for High Throughput Screening of Cancer Cells. The company believes this patent validates its innovative drug discovery approach, leveraging high throughput screening (HTS) to identify effective anti-cancer compounds. This process has led to the development of multiple promising drug candidates, including RCC-33 for colorectal cancer.
Cannabics Pharmaceuticals (OTCQB: CNBX) announced a collaboration with Purisys for the supply of GMP-grade APIs for its colorectal cancer drug candidate, RCC-33. The agreement includes support for the IND filing process with the FDA. This partnership is aimed at ensuring high purity and regulatory compliance. Purisys, recognized for its expertise in cannabinoid APIs, will assist CNBX in launching Phase I/II clinical trials in 2022. This collaboration marks a significant development in CNBX's efforts to advance its cannabinoid-based cancer treatments.
Cannabics Pharmaceuticals Inc. (OTC: CNBX) announced that Dr. Yonina Tova, a member of its Scientific Advisory Board, will attend the ASRT Radiation Therapy Conference in Chicago on October 26, 2021. The company emphasized its commitment to integrating cannabinoid-based treatments, including its colorectal cancer drug candidate RCC-33, into existing cancer therapies. Additionally, Cannabics has expanded its advisory board to include leading melanoma and hematology experts, enhancing its research capabilities.
Cannabics Pharmaceuticals Inc. (OTC: CNBX) announced the addition of Dr. Yonina Tova, an esteemed Radiation Oncologist, to its Board of Advisors on October 25, 2021. Dr. Tova, who is certified by the American Board of Radiology, brings extensive experience in cancer treatment through radiation therapy. The company is advancing its drug candidate RCC-33 for colorectal cancer and aims to enhance its expert clinical team as it prepares for Phase I/II studies. Dr. Tova's expertise is expected to significantly impact the company's efforts to improve patient outcomes.
Cannabics Pharmaceuticals (OTC: CNBX) announced that EDISON Group released a QuickView publication regarding the company, focusing on its plans for Phase I/II(a) clinical studies for the colorectal cancer treatment drug candidate RCC-33. The report also highlights recent updates on the company's activities. Cannabics is recognized as a leader in developing cannabinoid-based treatments for cancer. The company aims to advance its intellectual property portfolio and has recently expanded its board of advisors and directors with various medical experts.